N/A
Completed N=463
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
Source: ClinicalTrials.gov NCT02515279 ↗Enrolled (actual)
463
Serious AEs
3.9%
Results posted
Feb 2016
Primary outcomePrimary: Percentage of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) — 44.28; 3.9 percentage of participants
Summary
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) |
44.28; 3.9 | — |
| PRIMARY Percentage of Participants With End of Treatment Response |
83.8; 9.7 | — |
| PRIMARY Percentage of Participants With Sustained Virologic Response 24 (SVR24) |
26.6 | — |
Eligibility Criteria
Inclusion Criteria
- Ongoing treatment with peginterferon alfa-2a and ribavirin at the discretion of the prescribing physician
- HCV infection
Exclusion Criteria
- None specified
Data sourced from ClinicalTrials.gov (NCT02515279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.